The healthcare sector will be one area of secular growth over the next decade. Several demand drivers will benefit the best healthcare stocks to buy across the entire value chain.First, let’s highlight the major healthcare tailwinds starting with an aging population. The baby boomer generation (20% of the U.S. population) is transitioning into older age. This shift will create a surging demand for healthcare services and products such as insurance, pharmaceuticals, medical devices and hospitals.Indeed, esti ...

NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the District of Colorado on behalf of those who acquired Biogen, Inc (“Biogen” or the “Company”) (NASDAQ: BIIB) securities during the period of February 3, 2022 through February 13, 2024, inclusive (“the Class Period”). Investors have until July 22, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit. [Click here t ...

NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq: BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/biogen-inc-investigation. Why is Biogen being Sued? On May 22, 2024, Biogen was sued for violations of the federal securities laws. The complaint alleges that between February 3, 2022 and F ...

Biogen Inc. (NASDAQ:BIIB) Goldman Sachs 45th Annual Global Healthcare Conference June 12, 2024 10:40 AM ET Company Participants Alisha Alaimo - Head and President of North-America Chuck Triano - Head of IR Conference Call Participants Salveen Richter - Goldman Sachs Salveen Richter Great. Good morning, everyone. Thank you so much for joining us. Really pleased to have the Biogen team here with us. We have Alisha Alaimo who's the President, Head of North America; and Chuck Triano, Head of IR. With that, let ...

Biogen Inc. (NASDAQ:BIIB) Goldman Sachs 45th Annual Global Healthcare Conference June 12, 2024 10:40 AM ET Company Participants Alisha Alaimo - Head and President of North-America Chuck Triano - Head of IR Conference Call Participants Salveen Richter - Goldman Sachs Salveen Richter Great. Good morning, everyone. Thank you so much for joining us. Really pleased to have the Biogen team here with us. We have Alisha Alaimo who's the President, Head of North America; and Chuck Triano, Head of IR. With that, let ...

PALM BEACH, Fla., June 11, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - In the last twenty years, the amount of people with multiple sclerosis (MS) in the United States has more than doubled. In 2000, it was estimated by the National Multiple Sclerosis Society that around 400,000 Americans had the disease. In 2017, that estimate had jumped to 900,000. Although estimates between studies differ, it's commonly accepted that about 800,000-900,000 individuals in the United States suffer from MS, out ...

NEW YORK, June 11, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq: BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/biogen-inc-investigation. Why is Biogen being Sued? On May 22, 2024, Biogen was sued for violations of the federal securities laws. The complaint alleges that between February 3, 2022 and F ...

LOS ANGELES, June 10, 2024 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB).Class Period: February 3, 2022 – February 13, 2024Lead Plaintiff Deadline: July 22, 2024If you are a shareholder who suffered a loss, click here to participate.The complaint filed alleges that, throughout the Class Period, Defendants failed to disclose to i ...

Biogen (BIIB) and Japanese partner Eisai announced that the FDA has accepted Eisai’s supplemental biologics license application (sBLA) seeking approval for a maintenance intravenous (“IV”) dosing version of Leqembi for the treatment of early Alzheimer’s disease. The FDA is expected to give its decision on the sBLA on Jan 25, 2025.Leqembi was approved as an injection for intravenous use by the FDA for early Alzheimer’s disease in the United States in July 2023. Leqembi is also approved in China and Japan. Re ...

NEW YORK, June 10, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Biogen Inc. (NASDAQ: BIIB).Shareholders who purchased shares of BIIB during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/biogen-loss-submission-form/?id=83256&from=4 CLASS PERIOD: February 3, 2022 to February 13, 2 ...